In 2009, Dr. Patrick Soon-Shiong established research, development and manufacturing capabilities through the NantWorks portfolio of companies, which are focused on healthcare transformation through the convergence of a wide range of scientific discoveries, research and technologies.

NantPharma currently manufactures and markets crude heparin in a concentrated eluate form, processed from porcine intestinal mucosa collected exclusively from slaughterhouses in the United States and Europe.